Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its ...
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Stifel analyst Rick Wise lowered the firm’s price target on Johnson & Johnson to $155 from $170 and keeps a Hold rating on the shares.
Whether it's through stocks, bonds, ETFs, or other types of securities, all investors love seeing their portfolios score big returns. But when you're an income investor, your primary focus is ...
The 47-year-old millionaire tech mogul posted screenshots showing data from an overnight erection-tracking machine for both himself and his 19-year-old son, Talmage.
Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a ...